Cross-border biotechnology collaborations between the United States and China are encountering increased complexity due to heightened US oversight of investment and technology sharing. Industry analysts predict a potential, though modest, decrease in deal volume as Washington intensifies restrictions. Diederik Stadig of ING Research attributes this to growing geopolitical scrutiny of these transactions. While regulatory obstacles are rising, the overall trend of collaboration is expected to continue. The increased scrutiny focuses on safeguarding sensitive technologies and national security interests. This shift impacts the financial landscape for biotech companies operating across both nations, requiring more thorough due diligence and potentially longer approval processes. Despite challenges, the fundamental drivers for collaboration remain present.